Conclusions GLP-1RAs provide a novel approach for treating obesity-related asthma by simultaneously targeting metabolic dysfunction and airway inflammation
The implications for cognitive function and systemic health are significant, though research continues to clarify the full scope of these effects
21, 2025, the FDA gave compounding pharmacies a deadline to cease distribution of compounded versions of FDA-approved Ozempic, Wegovy, and Rybelsus
The peptide does not cause fluid retention that would register as weight gain
From a development scientists perspective, BPC-157 looks like a very promising mechanistic story with compelling preclinical proof-of-concept, but still at the interesting preclinical lead stage rather than known effective therapy. When comparing ARA-290 vs BPC-157 for injury recovery, ARA-290 currently leans toward nerve- and inflammation-focused recovery, while BPC-157 leans toward structural tissue repairmostly supported by animal data
H., Gallagher, B